 |
 |
|
|
|  PubMed
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3 April 2001 | Volume 134 Issue 7 | Pages 550-560
Purpose: Congestive heart failure is an important cause of patient morbidity and mortality. Although several randomized clinical trials have compared ß-blockers with placebo for treatment of congestive heart failure, a meta-analysis quantifying the effect on mortality and morbidity has not been performed recently.
Data Sources: The MEDLINE, Cochrane, and Web of Science electronic databases were searched from 1966 to July 2000. References were also identified from bibliographies of pertinent articles.
Study Selection: All randomized clinical trials of ß-blockers versus placebo in chronic stable congestive heart failure were included.
Data Extraction: A specified protocol was followed to extract data on patient characteristics, ß-blocker used, overall mortality, hospitalizations for congestive heart failure, and study quality.
Data Synthesis: A hierarchical random-effects model was used to synthesize the results. A total of 22 trials involving 10 135 patients were identified. There were 624 deaths among 4862 patients randomly assigned to placebo and 444 deaths among 5273 patients assigned to ß-blocker therapy. In these groups, 754 and 540 patients, respectively, required hospitalization for congestive heart failure. The probability that ß-blocker therapy reduced total mortality and hospitalizations for congestive heart failure was almost 100%. The best estimates of these advantages are 3.8 lives saved and 4 fewer hospitalizations per 100 patients treated in the first year after therapy. The probability that these benefits are clinically significant (>2 lives saved or >2 fewer hospitalizations per 100 patients treated) is 99%. Both selective and nonselective agents produced these salutary effects. The results are robust to any reasonable publication bias.
Conclusions: ß-Blocker therapy is associated with clinically meaningful reductions in mortality and morbidity in patients with stable congestive heart failure and should be routinely offered to all patients similar to those included in trials.
Author and Article Information
From the Centre Hospitalier de l'Université de Montréal, McGill University, and Montreal General Hospital, Montreal, Quebec; and University Health Network and Mount Sinai Hospitals, Toronto, Ontario, Canada.
Grant Support: Drs. Brophy and Joseph receive funding from Les Fonds de la Recherche en Santé du Québec.
Requests for Single Reprints: James Brophy, MD, PhD, Service de Cardiologie, Centre Hospitalier de l'Université de Montréal, Pavillon Notre-Dame, 1560 rue Sherbrooke Est, Montreal, Quebec H2L 4M1, Canada; e-mail, jbroph{at}po-box.mcgill.ca.
Current Author Addresses: Dr. Brophy: Service de Cardiologie, Centre Hospitalier de l'Université de Montréal, Pavillon Notre-Dame, 1560 rue Sherbrooke Est, Montreal, Quebec H2L 4M1, Canada.
Dr. Joseph: Department of Epidemiology and Biostatistics, McGill University, 1650 Cedar Avenue, Montreal, Quebec H3G 1A4, Canada.
Dr. Rouleau: Department of Medicine, University Health Network and Mount Sinai Hospital, 200 Elizabeth Street, Eaton North 13-212, Toronto, Ontario M5G 2C4, Canada.
Author Contributions: Conception and design: J.M. Brophy, L. Joseph.
Analysis and interpretation of the data: J.M. Brophy, L. Joseph, J.L. Rouleau.
Drafting of the article: J.M. Brophy, L. Joseph, J.L. Rouleau.
Critical revision of the article for important intellectual content: J.M. Brophy, L. Joseph, J.L. Rouleau.
Final approval of the article: J.M. Brophy, L. Joseph, J.L. Rouleau.
Provision of study materials or patients: Statistical expertise: J.M. Brophy, L. Joseph.
Administrative, technical, or logistic support: J.M. Brophy, J.L. Rouleau.
Collection and assembly of data: J.M. Brophy. ARTICLE
ß-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  F. A. McAlister, N. Wiebe, J. A. Ezekowitz, A. A. Leung, and P. W. Armstrong Meta-analysis: {beta}-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure Ann Intern Med, June 2, 2009; 150(11): 784 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Massie, J. F. Collins, S. E. Ammon, P. W. Armstrong, J. G.F. Cleland, M. Ezekowitz, S. M. Jafri, W. F. Krol, C. M. O'Connor, K. A. Schulman, et al. Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial Circulation, March 31, 2009; 119(12): 1616 - 1624. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Kramer, L. H. Curtis, C. S. Dupree, D. Pelter, A. Hernandez, M. Massing, and K. J. Anstrom Comparative Effectiveness of {beta}-Blockers in Elderly Patients With Heart Failure Arch Intern Med, December 8, 2008; 168(22): 2422 - 2428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Fonarow, W. T. Abraham, N. M. Albert, W. G. Stough, M. Gheorghiade, B. H. Greenberg, C. M. O'Connor, J. L. Sun, C. W. Yancy, J. B. Young, et al. Influence of Beta-Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure Findings From the OPTIMIZE-HF Program. J. Am. Coll. Cardiol., July 15, 2008; 52(3): 190 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G. Carruthers Reminders in echocardiography reports increased use of blockers in reduced left ventricular ejection fraction Evid. Based Med., December 1, 2007; 12(6): 185 - 185. [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members, I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur. Heart J., October 1, 2007; 28(19): 2375 - 2414. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Leibovici, A. Gafter-Gvili, M. Paul, N. Almanasreh, E. Tacconelli, S. Andreassen, A.D. Nielsen, U. Frank, R. Cauda, and for the TREAT Study Group Relative tachycardia in patients with sepsis: an independent risk factor for mortality QJM, October 1, 2007; 100(10): 629 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Bracken, E. Mannucci, M. Monami, N. Marchionni, G. A. Diamond, S. Kaul, A. S. Brett, S. E. Nissen, K. Wolski, B. M. Psaty, et al. Rosiglitazone and Cardiovascular Risk N. Engl. J. Med., August 30, 2007; 357(9): 937 - 940. [Full Text] [PDF]
|
|
|
|
|
|
S. Bangalore, F. H. Messerli, J. B. Kostis, and C. J. Pepine Cardiovascular Protection Using Beta-Blockers: A Critical Review of the Evidence J. Am. Coll. Cardiol., August 14, 2007; 50(7): 563 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chugh, K. Reinier, and E. C. Stecker Learning From a Real-World Analysis of Implantable Cardioverter-Defibrillator Recipients: Comorbidities Matter J. Am. Coll. Cardiol., June 26, 2007; 49(25): 2416 - 2418. [Full Text] [PDF]
|
|
|
|
 |
|
 E. B Friedrich and M. Bohm MANAGEMENT OF END STAGE HEART FAILURE Heart, May 1, 2007; 93(5): 626 - 631. [Full Text] [PDF]
|
|
|
|
|
|
M. Rivero-Ayerza, D. A.M.J. Theuns, H. M. Garcia-Garcia, E. Boersma, M. Simoons, and L. J. Jordaens Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials Eur. Heart J., November 2, 2006; 27(22): 2682 - 2688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bourque, C. M. O'Connor, and E. J. Velazquez Letter by Bourque et al Regarding Article, "Changing Incidence and Survival for Heart Failure in a Well-Defined Older Population, 1970-1974 and 1990-1994" Circulation, August 15, 2006; 114(7): e255 - e255. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Khan and F. A. McAlister Re-examining the efficacy of {beta}-blockers for the treatment of hypertension: a meta-analysis Can. Med. Assoc. J., June 6, 2006; 174(12): 1737 - 1742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Ko, J. V. Tu, F. A. Masoudi, Y. Wang, E. P. Havranek, S. S. Rathore, A. M. Newman, L. R. Donovan, D. S. Lee, J. M. Foody, et al. Quality of Care and Outcomes of Older Patients With Heart Failure Hospitalized in the United States and Canada Arch Intern Med, November 28, 2005; 165(21): 2486 - 2492. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. N. Singh {beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S3 - S14. [Abstract] [PDF]
|
|
|
|
 |
|
 D. S. Lee, J. V. Tu, D. N. Juurlink, D. A. Alter, D. T. Ko, P. C. Austin, A. Chong, T. A. Stukel, D. Levy, and A. Laupacis Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure JAMA, September 14, 2005; 294(10): 1240 - 1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. A. Ioannidis Contradicted and Initially Stronger Effects in Highly Cited Clinical Research JAMA, July 13, 2005; 294(2): 218 - 228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ducharme, O. Doyon, M. White, J. L. Rouleau, and J. M. Brophy Impact of care at a multidisciplinary congestive heart failure clinic: a randomized trial Can. Med. Assoc. J., July 5, 2005; 173(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Weiner, T E Stump, C M Callahan, J N Lewis, and C J McDonald Pursuing integration of performance measures into electronic medical records: beta-adrenergic receptor antagonist medications Qual. Saf. Health Care, April 1, 2005; 14(2): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nanthakumar, A. E. Epstein, G. N. Kay, V. J. Plumb, and D. S. Lee Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: A pooled analysis of 10 primary prevention trials J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2166 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ezekowitz, F. A. McAlister, K. H. Humphries, C. M. Norris, M. Tonelli, W. A. Ghali, M. L. Knudtson, and APPROACH Investigators The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1587 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. McAlister, J. A. Ezekowitz, N. Wiebe, B. Rowe, C. Spooner, E. Crumley, L. Hartling, T. Klassen, and W. Abraham Systematic Review: Cardiac Resynchronization in Patients with Symptomatic Heart Failure Ann Intern Med, September 7, 2004; 141(5): 381 - 390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Gluckman, B. Baranowski, M. D. Ashen, C. A. Henrikson, M. McAllister, J. B. Braunstein, and R. S. Blumenthal A Practical and Evidence-Based Approach to Cardiovascular Disease Risk Reduction Arch Intern Med, July 26, 2004; 164(14): 1490 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chatterjee The Fear of {beta}-Blocker Therapy in Heart Failure: Time to Forget Arch Intern Med, July 12, 2004; 164(13): 1370 - 1371. [Full Text] [PDF]
|
|
|
|
|
|
D. T. Ko, P. R. Hebert, C. S. Coffey, J. P. Curtis, J. M. Foody, A. Sedrakyan, and H. M. Krumholz Adverse Effects of {beta}-Blocker Therapy for Patients With Heart Failure: A Quantitative Overview of Randomized Trials Arch Intern Med, July 12, 2004; 164(13): 1389 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P McElduff, G Lyratzopoulos, R Edwards, R F Heller, P Shekelle, and M Roland Will changes in primary care improve health outcomes? Modelling the impact of financial incentives introduced to improve quality of care in the UK Qual. Saf. Health Care, June 1, 2004; 13(3): 191 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kernis, K. J. Harjai, G. W. Stone, L. L. Grines, J. A. Boura, W. W. O'Neill, and C. L. Grines Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1773 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Salpeter, T. M. Ormiston, and E. E. Salpeter Meta-Analysis: Respiratory Tolerance to Regular {beta}2-Agonist Use in Patients with Asthma Ann Intern Med, May 18, 2004; 140(10): 802 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Thornton and A. Ahmed Angiotensin-converting enzyme inhibitors, beta-blockers, and mortality in systolic heart failure J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1333 - 1333. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Shlipak Pharmacotherapy for Heart Failure in Patients with Renal Insufficiency Ann Intern Med, June 3, 2003; 138(11): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Brophy, P. Belisle, and L. Joseph Evidence for Use of Coronary Stents: A Hierarchical Bayesian Meta-Analysis Ann Intern Med, May 20, 2003; 138(10): 777 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Reed, P. W. Dillingham, A. H. Briggs, D. L. Veenstra, and S. D. Sullivan A Bayesian Approach to Aid in Formulary Decision Making: Incorporating Institution-Specific Cost-Effectiveness Data with Clinical Trial Results Med Decis Making, May 1, 2003; 23(3): 252 - 264. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Soler-Soler and D. Garcia-Dorado How to best to counteract the enemies? By blocking neurohormonal activation Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G45 - G50. [Abstract] [PDF]
|
|
|
|
|
|
Y. Wu, J. Temple, R. Zhang, I. Dzhura, W. Zhang, R. Trimble, D. M. Roden, R. Passier, E. N. Olson, R. J. Colbran, et al. Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy Circulation, September 3, 2002; 106(10): 1288 - 1293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Philipp, M. Brede, and L. Hein Physiological significance of alpha 2-adrenergic receptor subtype diversity: one receptor is not enough Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2002; 283(2): R287 - R295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. McCafferty, D. Sorbellini, and P. Cianci Telemetry to Home: Successful Discharge of Patients With Ventricular Assist Devices Crit. Care Nurse, June 1, 2002; 22(3): 43 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 P. Merlet, L. Hittinger, J. L. Dubois-Rande, and A. Castaigne Myocardial Adrenergic Dysinnervation in Dilated Cardiomyopathy: Cornerstone or Epiphenomenon? J. Nucl. Med., April 1, 2002; 43(4): 536 - 539. [Full Text] [PDF]
|
|
|
|
|
|
J. M. Foody, M. H. Farrell, and H. M. Krumholz {beta}-Blocker Therapy in Heart Failure: Scientific Review JAMA, February 20, 2002; 287(7): 883 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Farrell, J. M. Foody, and H. M. Krumholz {beta}-Blockers in Heart Failure: Clinical Applications JAMA, February 20, 2002; 287(7): 890 - 897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chatterjee Refractory heart failure--drugs and devices Eur. Heart J., December 2, 2001; 22(24): 2227 - 2230. [PDF]
|
|
|
|
 |
|
 Beta-Blockers for CHF: An Updated Meta-Analysis Journal Watch Cardiology, June 1, 2001; 2001(601): 5 - 5. [Full Text]
|
|
|
|
|
|
E. Braunwald Expanding Indications for Beta-Blockers in Heart Failure N. Engl. J. Med., May 31, 2001; 344(22): 1711 - 1712. [Full Text] [PDF]
|
|
